^
Association details:
| Biomarker: | EGFR mutation + RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Brief report: Response to pralsetinib observed in meningeal-metastatic EGFR-mutant NSCLC with acquired RET fusion
Published date:
05/18/2022
Excerpt:
We reported an EGFR-mutant NSCLC patient with acquired RET fusions and meningeal metastasis treated with pralsetinib and Osimertinib...This patient achieved a partial response, indicating that pralsetinib combined with osimertinib may be clinically beneficial for meningeal metastasis in patients harboring acquired co-existent RET fusions.
DOI:
https://doi.org/10.1016/j.jtocrr.2022.100343
